GSK-364735
Resistance Profile of the Integrase Inhibitor S/GSK-364735
- 2/10/08
Integrase
Inhibitor GSK364735 is Safe and Well-tolerated in Phase I Study -
3/06/07
A Double-Blind, Parallel, Randomized, Placebo-Controlled,
Single and Repeat Dose Escalation Study to Investigate the Safety, Tolerability,
and Pharmacokinetics of the HIV Integrase Inhibitor GSK364735 in Healthy
Subjects (GRZ105655)
S Reddy and others. Poster 562. Copyright GlaxoSmithKline.
Used with permission, 2007. -
3/16/07
|
|
|
|
